{
    "ticker": "RDUS",
    "name": "Radius Health, Inc.",
    "description": "Radius Health, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for patients with osteoporosis and other serious bone diseases. Established in 2003 and headquartered in Cambridge, Massachusetts, Radius Health aims to address significant unmet medical needs in the treatment of bone health. The company's lead product, Tymlos (abaloparatide), is a peptide therapeutic indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Tymlos is designed to stimulate new bone formation, thereby reducing the risk of fractures. In addition to Tymlos, Radius is committed to advancing new therapies and has a robust pipeline that includes a variety of novel compounds targeting bone health and metabolic diseases. Radius Health's mission is to empower patients and enhance their quality of life through cutting-edge research and development in the field of bone health. The company is dedicated to collaborating with healthcare professionals, researchers, and patient advocacy groups to bring transformative therapies to market.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2003",
    "website": "https://www.radiuspharm.com",
    "ceo": "Danielle A. McGowan",
    "social_media": {
        "twitter": "https://twitter.com/RadiusHealth",
        "linkedin": "https://www.linkedin.com/company/radius-health-inc/"
    },
    "investor_relations": "https://ir.radiuspharm.com",
    "key_executives": [
        {
            "name": "Danielle A. McGowan",
            "position": "CEO"
        },
        {
            "name": "Jeffrey A. Karp",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Tymlos (abaloparatide)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Radius Health, Inc. | Innovative Therapies for Bone Health",
        "meta_description": "Radius Health, Inc. focuses on developing innovative therapeutics for osteoporosis and serious bone diseases. Learn about their lead product, Tymlos, and ongoing research.",
        "keywords": [
            "Radius Health",
            "Osteoporosis",
            "Tymlos",
            "Bone Health",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Radius Health known for?",
            "answer": "Radius Health is known for developing innovative therapeutics for osteoporosis and other serious bone diseases."
        },
        {
            "question": "Who is the CEO of Radius Health?",
            "answer": "Danielle A. McGowan is the CEO of Radius Health, Inc."
        },
        {
            "question": "Where is Radius Health headquartered?",
            "answer": "Radius Health is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is Radius Health's main product?",
            "answer": "Radius Health's main product is Tymlos (abaloparatide), used for the treatment of postmenopausal women with osteoporosis."
        },
        {
            "question": "When was Radius Health founded?",
            "answer": "Radius Health was founded in 2003."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "VRTX",
        "BMRN"
    ],
    "related_stocks": [
        "GILD",
        "ABBV",
        "JNJ",
        "PFE"
    ]
}